Key result
Treatment of human umbilical vein endothelial cells with IGFs inhibited urokinase-type PA activity, reduced its mRNA by 50%, and decreased prostaglandins and COX-2 mRNA.
Why the study?
Do IGFs alter prostaglandin synthesis and plasminogen activator activity in human umbilical vein endothelial cells?
Do IGFs alter prostaglandin synthesis and plasminogen activator activity in human umbilical vein endothelial cells?
IGFs decrease prostaglandin synthesis and urokinase-type plasminogen activator activity in HUVECs, suggesting a potential role in the endothelial dysfunction observed in preeclampsia.
Answers are grounded in this paper and cite their sources.
May implicate IGFs in preeclamptic endothelial fibrinolysis; leaves open clinical relevance pending in vivo data.
IGFs seem to contribute to the endothelial dysfunction observed in some vascular diseases. Because locally increased IGFs levels were detected in the preeclamptic fetoplacental unit, we hypothesized their involvement in the dysregulation of fibrinolysis and vascular tone typically observed in the fetoplacental compartment in this pregnancy disease. Therefore, in human umbilical vein endothelial cells (HUVECs), the potential effect of IGFs on the synthesis of plasminogen activators (PAs), PA inibitor-1 (PAI-1), and vasodilator and vasoconstrictor prostaglandins (PGs) was investigated. Moreover, in HUVECs treated with IGFs, the expression of cyclooxygenase (COX)-2, the rate-limiting enzyme in PG synthesis, was evaluated.HUVECs were treated for 24 h with IGFs (1-100 ng/ml) or IL-1beta (0.1 ng/ml). PA, PAI-1, and COX-2 mRNA was determined by RT-PCR and PG release and PA activity by RIA and colorimetric assay, respectively.We demonstrated an inhibition of urokinase-type PA activity and a 50% reduction of urokinase-type PA mRNA in HUVECs treated with IGFs. No effect was seen on PAI-1. Finally, both IGFs significantly decreased all PGs tested and COX-2 mRNA, whereas, as expected, IL-1beta had an opposite effect. In conclusion, our results suggest for IGFs a potential involvement in the endothelial dysfunction observed in preeclamptic fetoplacental unit.
No takes yet. Share an insight, caveat, or question.
Miceli et al. (2005) studied Endothelial dysfunction in preeclampsia. Insulin-Like Growth Factor I and II (IGFs) vs. IL-1beta (0.1 ng/ml) or untreated control was evaluated on Synthesis of plasminogen activators, PAI-1, prostaglandins, and COX-2 expression. Treatment of human umbilical vein endothelial cells with IGFs inhibited urokinase-type PA activity, reduced its mRNA by 50%, and decreased prostaglandins and COX-2 mRNA.
Synapse has enriched 10 related papers. Consider them for comparative context: